Regulatory approval received for acquisition of Nitin Lifesciences
Further to our announcement on 20th October 2015 that Recipharm will acquire a majority stake (74%) in Nitin Lifesciences Limited, the Indian Foreign Investment and Promotion Board has now granted approval for this transaction to take place. Closing is expected to take place by the end of Q1 2016. For more information please visit www.recipharm.com or contact:Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 00Björn Westberg, CFO, ir@recipharm.com, telephone: +46 8 602 46 20 This information is published in accordance with the Swedish Securities Market Act,